Primary Nodal Marginal Zone B-Cell Lymphoma Arising From More Than One Clonal Neoplastic Population

2000 ◽  
Vol 124 (12) ◽  
pp. 1816-1819
Author(s):  
Clara N. Finch ◽  
Margaret Nichols ◽  
Antony Shrimpton ◽  
Dating Liu ◽  
Robert E. Hutchison

Abstract Primary nodal marginal zone B-cell lymphoma is an uncommon monoclonal B-cell lymphoproliferative disorder. We report a case of a 79-year-old woman who presented with generalized lymphadenopathy. Histologic and immunohistochemical examinations of biopsy sections from an axillary lymph node were consistent with nodal marginal zone B-cell lymphoma. Flow cytometry analysis showed 2 distinct clonal B-cell populations expressing λ or κ light chain restriction. Subsequently, genomic deoxyribonucleic acid (DNA) isolated from a paraffin-embedded lymph node section was analyzed for the presence of gene rearrangements. Polymerase chain reaction (PCR) analysis of immunoglobulin heavy chain genes revealed 3 rearranged DNA bands, confirming the presence of more than one clonal B-cell population. These immunophenotypic and genotypic findings have not been previously described in association with this type of lymphoma. To our knowledge, this represents the first reported case of biclonal nodal marginal zone B-cell lymphoma.

2000 ◽  
Vol 38 (5-6) ◽  
pp. 605-610
Author(s):  
Francesco Bertoni ◽  
Roman Müllenbach ◽  
Massimo Broggini ◽  
Enrico Roggero ◽  
Franco Cavalli ◽  
...  

Blood ◽  
2015 ◽  
Vol 126 (23) ◽  
pp. 1533-1533 ◽  
Author(s):  
Veronika Bachanova ◽  
Frederick Lansigan ◽  
Donald P. Quick ◽  
Daniel Vlock ◽  
Stephen Gillies ◽  
...  

Abstract DI-Leu16-IL2 immunocytokine is a recombinant fusion protein composed of interleukin 2 (IL2) and a CD20 targeting monoclonal antibody. Pre-clinical studies have shown it maintains the activities of both antibody and cytokine components but is also involved in tumor targeting, engagement of the immune system and induction of an anti-cancer vaccine effect. In a SCID mouse model,DI-Leu16-IL2 is more effective than the individual components (IL-2 and CD20) given either alone or in combination (Gillies SD; 2005). DI-Leu16-IL2 administered intravenously to 8 relapsed/refractory Non-Hodgkin's Lymphoma (NHL) patients at a maximum dose of dose of 0.5 mg/m2 resulted in 1 complete, 1 possible partial response and 4 patients with stable disease (Nakamura R; 2013). In this multicenter open label, dose escalation trial the safety, efficacy and tolerability of subcutaneously (SC) administered DI-Leu16-IL2 was evaluated as well as the maximum tolerated dose (MTD) and optimal biological dose in patients with relapsed or refractory B cell CD20 positive lymphoma (NCT01874288). DI-Leu16-IL2 was administered on three consecutive days every 21 days up to 6 cycles. Peripheral B cell depletion was achieved with low-dose rituximab (50mg/m2) on day 1 if needed to keep rituximab levels >10µg/mL. The starting dose was 0.5 mg/m2 and followed a modified accelerated titration until dose limited toxicity (DLT) occurred. To be evaluable for response patients had to receive at least 2 cycles of DI-Leu16-IL2 and were then evaluated by PET/CT imaging. To date, 13 patients in 3 cohorts have been enrolled. The median age is 63 years (range, 48-83 years). Ten patients had diffuse large B cell lymphoma, 2 follicular and 1 marginal zone NHL. All were previously treated with rituximab-containing chemotherapy - median of 3 (range 1-6) prior regimens, including radiation therapy (n=5) and autologous transplantation (n=3). All patients had relapsed or refractory disease with biopsy-confirmed tumor cells expressing CD20. DI-Leu16-IL2 dose levels were 0.5 mg/m2 (n=3), 1 mg/m2 (n=3), 2 mg/m2 (n=7). DI-Leu16-IL2 was detectable in the serum at the lowest dose level. Median number of cycles were 4 (range 1-11). No DLTs have been observed. The most common drug-related adverse events (AEs) were grade 1-2 transient skin reactions with erythema, painless induration of injection site, pruritus, edema and mild constitutional symptoms (grade 1-2 chills, low-grade fever, fatigue, low appetite) suggesting an immune stimulatory response. Lymphocyte margination occurred with nadir of 0.3x103 /mL for median 2.7 days (range 1-5). Two grade 3 non-DLT toxicities (diarrhea and QTc prolongation with pre-existing RBBB) resulted in DI-Leu16-IL2 dose reduction. Transiently prolonged QTc (grade 1-2) occurred in 3 additional patients. Routine laboratory monitoring revealed grade 1-2 transient eosinophilia, anemia and thrombocytopenia in most subjects, grade 1-2 neutropenia (n=3) without neutropenic fever, grade 1 elevation of alkaline phosphatase or bilirubin. All AEs resolved completely within one week. Twelve patients are evaluable for response. After 2 cycles, tumor regression or stabilization was noted in 10 of 12 patients with mean tumor reduction of 30% (range 0%-80%). Six had sustained disease control after 4 cycles. One patient with small tumor bulk marginal zone lymphoma achieved a complete response by PET criteria, 3 patients had a partial response (55%, 55% and 80% tumor size reduction) and continue on therapy. Stable disease (SD) response was observed in all dose cohorts; best responses occurred at the highest dose level (2mg/m2) administered thus far. Three patients have had SD for up to 1 year. In conclusion, we have observed promising clinical efficacy of the novel immunocytokine DI-Leu16-IL2 in relapsed/refractory B cell NHL. SC administration has permitted higher doses than could be achieved with IV treatment and the MTD has yet to be reached. DI-Leu16-IL2 is biologically active in doses up to 2mg/m2. Repetitive SC dosing elicits clinical immune activation associated with clinical activity. Further dose escalation of DI-Leu16-IL2 is in progress. Prior DI-Leu16-IL2 therapy After 2 cycles at dose 2mg/m2 Figure 1. 65 year old female with diffuse large B cell lymphoma treated at dose level 2mg/m2 received 2 cycles of DI-Leu16-IL2. Treatment resulted in partial regression of multiple lymph node sites. Figure 1. 65 year old female with diffuse large B cell lymphoma treated at dose level 2mg/m2 received 2 cycles of DI-Leu16-IL2. Treatment resulted in partial regression of multiple lymph node sites. Disclosures Bachanova: Seattle Genetics Inc.: Consultancy, Research Funding.


2011 ◽  
Vol 44 (3) ◽  
pp. 252-258
Author(s):  
Kimitaka Tanaka ◽  
Eiji Tamoto ◽  
Yoshihiro Nakakubo ◽  
Tomoo Okushiba ◽  
Takeshi Kawamura ◽  
...  

Blood ◽  
1989 ◽  
Vol 73 (2) ◽  
pp. 573-578
Author(s):  
ST Traweek ◽  
K Sheibani ◽  
CD Winberg ◽  
RR Mena ◽  
AM Wu ◽  
...  

Monocytoid B-cell lymphoma (MBCL) is a newly recognized B-cell neoplasm of uncertain histogenesis. The cytologic features of the neoplastic monocytoid B lymphocytes are virtually identical to those of hairy cell leukemia (HCL). As with HCL, progression of MBCL to a higher histologic grade is very unusual. However, whereas circulating leukemic cells are a characteristic feature of HCL, peripheral blood involvement has not been reported in MBCL. We recently studied a patient with MBCL of the spleen and axillary lymph nodes who developed peripheral blood involvement by MBCL cells. Unlike the cells of HCL, the circulating MBCL cells exhibited strong acid phosphatase activity that was tartrate sensitive. The leukemic cells had the antigenic phenotype IgM lambda, CD20+, CD11c+, CD5-, CD25(TAC)-, and PCA-1-. Immunogenetic studies of both lymph node and peripheral blood cells revealed identical immunoglobulin heavy-chain gene rearrangements. When compared with a series of HCL, the immunophenotype was similar except for the absence of PCA-1 and TAC. Progression of the MBCL to a large cell lymphoma, also expressing IgM lambda, was documented in an abdominal lymph node of this patient. Therefore, although rare, peripheral blood involvement by lymphoma cells may occur during the course of MBCL and should be distinguished from HCL with cytochemical and immunophenotypic studies. In addition, comparison of the clinical, pathologic, and immunologic features of MBCL with those of other low-grade B-cell neoplasms suggests that a close lineage relationship exists between MBCL and HCL.


Blood ◽  
2007 ◽  
Vol 110 (11) ◽  
pp. 4426-4426
Author(s):  
Stefano Pulini ◽  
Francesco Angrilli ◽  
Simona Falorio ◽  
Giuseppe Fioritoni

Abstract The simultaneous manifestation of different lymphomas in the same patient or in the same tissue is defined composite lymphoma. Although reports of synchronous or metachronous Hodgkin’s lymphoma (HL) and Non Hodgkin’s lymphoma (NHL) are not uncommon in the literature, the biologic relationship of the 2 malignancies is often unclear. Primary cutaneous B-cell lymphomas (pCBCLs) have been recognized as distinct clinicopathologic entities; they represent a wide spectrum of lymphoproliferative disorders separated from of B-cell NHL secondarily involving the skin and cutaneous B-cell pseudolymphomas. As regarding pCBCLs, a concomitant diagnosis of HL has been described very rarely. This is the case of a caucasian man affected by primary cutaneous follicolar B cell lymphoma (pCFCL). He presented grouped red plaques located on the nape, abdomen, shoulders, arms and even some little tumors surrounded by erythematous papules. Complete staging procedures did show no evidence of extracutaneous disease. A subcutaneous interferon therapy was started, in some months the patient reached a complete remission, and a maintainance therapy was continued for about 2 years. After 15 years, at the age of 58, the patient presented a red to violaceous infiltrated solitary plaque on the back, appeared about 2 months before. The lesion was completely excised and the biopsy showed a diffuse dermal infiltrate, not involving the epidermis, structured in follicle with reactive germinal centers; they were surrounded by small sized monomorphic lymphocytes with irregular nuclei and pale cytoplasm, showing the following immunophenotype pattern: CD20+, CD3−, IRTA+, CD10−, BCL6−, BCL2+, low proliferative index. A plasmacellullar CD138+ and CD79a+ population was at the periphery of the infiltrates, with monotypic expression of cytoplasmic k chain. The whole picture was interpreted as primary cutaneous marginal zone B-cell lymphoma (pCMZL). The association with Borrelia burgdorferi infection, sometimes described in pCMZL, wasn’t demonstrated. The patient presented a large right axillary lymph node that was excised and found to be unexpectly infiltrated by HL, mixed cellularity subtype. The patient underwent a standard baseline staging procedure with total body CT scan and bone marrow trephine biopsy; the latter resulted negative; the t(11;14) and t(14;18) rearrangements weren’t demonstrated in bone marrow; the CT did show no other suspected masses nor lymphoadenopathy, besides the clinically evident right axillary lymph node. A 18F-fluorodeoxyglucose positron emission tomography (FDG-PET) revealed sites of hyperactivity in the same right axillary region, but extending to the subclavian region and the thoracic region. The patient started chemoterapy (ABVD regimen), and at the end of 4 courses a whole body CT scan and FDG-PET resulted both negative. Now he is being treated with radiotherapy. If the nodal malignancy would have been diagnosed first, the skin lesion probably could have been misinterpreted as a secondary localization of HL; if the node biopsy wouldn’t have been performed we could diagnose B-cell NHL secondarily involving the skin (stage IV). Nevertheless the cutaneous and nodal infiltrates had a completely different general picture and phenotype. This case probably reflects a HL after 15-year remission of a pCBCL of low grade and the relationship between HL and the preceding pCFCL is not clear: casual or related to genetic predisposition for oncogenic events or favoured by an immunodeficiency state related to the first disease and the previous immunomodulatory therapy.


Blood ◽  
1989 ◽  
Vol 73 (2) ◽  
pp. 573-578 ◽  
Author(s):  
ST Traweek ◽  
K Sheibani ◽  
CD Winberg ◽  
RR Mena ◽  
AM Wu ◽  
...  

Abstract Monocytoid B-cell lymphoma (MBCL) is a newly recognized B-cell neoplasm of uncertain histogenesis. The cytologic features of the neoplastic monocytoid B lymphocytes are virtually identical to those of hairy cell leukemia (HCL). As with HCL, progression of MBCL to a higher histologic grade is very unusual. However, whereas circulating leukemic cells are a characteristic feature of HCL, peripheral blood involvement has not been reported in MBCL. We recently studied a patient with MBCL of the spleen and axillary lymph nodes who developed peripheral blood involvement by MBCL cells. Unlike the cells of HCL, the circulating MBCL cells exhibited strong acid phosphatase activity that was tartrate sensitive. The leukemic cells had the antigenic phenotype IgM lambda, CD20+, CD11c+, CD5-, CD25(TAC)-, and PCA-1-. Immunogenetic studies of both lymph node and peripheral blood cells revealed identical immunoglobulin heavy-chain gene rearrangements. When compared with a series of HCL, the immunophenotype was similar except for the absence of PCA-1 and TAC. Progression of the MBCL to a large cell lymphoma, also expressing IgM lambda, was documented in an abdominal lymph node of this patient. Therefore, although rare, peripheral blood involvement by lymphoma cells may occur during the course of MBCL and should be distinguished from HCL with cytochemical and immunophenotypic studies. In addition, comparison of the clinical, pathologic, and immunologic features of MBCL with those of other low-grade B-cell neoplasms suggests that a close lineage relationship exists between MBCL and HCL.


2003 ◽  
Vol 16 (2) ◽  
pp. 109-118 ◽  
Author(s):  
A.R. Garbuglia ◽  
T. Iezzi ◽  
M.R. Capobianchi ◽  
P. Pignoloni ◽  
A. Pulsoni ◽  
...  

Human TT virus (TTV) recently isolated from the serum of a patient with post-transfusion hepatitis does seem to have only hepatopathic effect. The virus can also infect the serum, peripheral blood mononuclear cells (PBMC) and bone marrow cells (BMC). Additional evidence has indicated that TTV is also present in the serum of people with hematopoietic malignancies. A significant increase in the incidence of lymphoma has recently been observed worldwide. We have investigated the presence of TTV DNA in lymph node biopsies of Italian patients affected with the most common lymphoma types in Western Countries: follicular lymphoma (FL), diffuse large B-cell lymphoma (DLBCL) and nodular sclerosis Hodgkin's disease (NS-HD). The possible role of a co-infection with Epstein-Barr virus (EBV) has also been investigated. DNA was extracted from 73 paraffin-embedded and 38 snap-frozen tissue specimens. From these, only 67 samples (29 paraffin-embedded and 38 snap-frozen tissues) from a total of 56 patients, were suitable for PCR analysis. TTV and EBV were detected by PCR using primers from two different conserved region in TTV and EBV genomes respectively. TTV DNA was detected in 30.0–50.0% of FL, 30.8% of DLBCL and 30.0–50.0% of NS-HD cases, depending on the primers used. All cases of non-specific reactive lymphoid hyperplasia (RLH), used as a putative control, were negative. The two major TTV genotypes circulating in Italy (G1 and G2) were detected in the analysed lymphoid neoplasms. EBV DNA was detected in 40.0% of FL, in 72.7% of DLBCL, in 80.0% of SN-HD and in 40.0% of RLH cases. EBV co-infection was found in 90% of TTV positive cases. The in situ hybridization assay was performed in TTV positive frozen samples. The significant prevalence of TTV DNA in lymphocytes circulating in the lymph nodes of both B-cell lymphomas and HD reported herewith suggests a possible implication of TTV infection in the development of these lymphoproliferative disorders.


Sign in / Sign up

Export Citation Format

Share Document